Symbols / NRXP
NRXP Chart
About
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital; and has as a partnership with neurocare Group AG to create a nationwide network of clinics to offer integrated neuroplastic care for the treatment of Depression, PTSD, and other serious mental health disorders. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 55.81M |
| Enterprise Value | 56.04M | Income | -38.06M | Sales | 242.00K |
| Book/sh | -0.93 | Cash/sh | 0.26 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | 14.50 | PEG | — |
| P/S | 230.60 | P/B | -2.03 | P/C | — |
| EV/EBITDA | -3.69 | EV/Sales | 231.55 | Quick Ratio | 0.26 |
| Current Ratio | 0.29 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.31 | EPS next Y | 0.13 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-17 | ROA | -97.83% |
| ROE | — | ROIC | — | Gross Margin | 59.92% |
| Oper. Margin | -17.02% | Profit Margin | 0.00% | Shs Outstand | 29.61M |
| Shs Float | 19.76M | Short Float | 10.00% | Short Ratio | 1.66 |
| Short Interest | — | 52W High | 3.84 | 52W Low | 1.58 |
| Beta | 1.96 | Avg Volume | 934.23K | Volume | 949.85K |
| Target Price | $36.75 | Recom | Strong_buy | Prev Close | $1.76 |
| Price | $1.89 | Change | 7.10% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$36.75
Mean price target
2. Current target
$1.89
Latest analyst target
3. DCF / Fair value
$1.82
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.89
Low
$25.00
High
$48.00
Mean
$36.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-18 | reit | BTIG | Buy → Buy | $25 |
| 2026-02-17 | main | D. Boral Capital | Buy → Buy | $34 |
| 2026-01-15 | reit | BTIG | Buy → Buy | $25 |
| 2026-01-05 | main | D. Boral Capital | Buy → Buy | $34 |
| 2026-01-02 | main | Ascendiant Capital | Buy → Buy | $48 |
| 2025-12-16 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-12-03 | main | D. Boral Capital | Buy → Buy | $34 |
| 2025-12-03 | reit | BTIG | Buy → Buy | $25 |
| 2025-12-02 | main | D. Boral Capital | Buy → Buy | $34 |
| 2025-11-17 | main | D. Boral Capital | Buy → Buy | $34 |
| 2025-11-10 | main | D. Boral Capital | Buy → Buy | $34 |
| 2025-10-30 | main | Ascendiant Capital | Buy → Buy | $47 |
| 2025-10-21 | main | D. Boral Capital | Buy → Buy | $34 |
| 2025-10-16 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-10-01 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-09-29 | main | D. Boral Capital | Buy → Buy | $34 |
| 2025-09-25 | main | D. Boral Capital | Buy → Buy | $34 |
| 2025-09-08 | main | D. Boral Capital | Buy → Buy | $34 |
| 2025-08-22 | main | D. Boral Capital | Buy → Buy | $34 |
| 2025-08-19 | main | D. Boral Capital | Buy → Buy | $31 |
- 70,000 patients' ketamine data may help FDA weigh suicide therapy - Stock Titan Wed, 14 Jan 2026 08
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting - GlobeNewswire ue, 17 Feb 2026 12
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Significant Increase in Short Interest - MarketBeat Fri, 30 Jan 2026 08
- NRx Pharmaceuticals Establishes $20 Million ATM Stock Program - The Globe and Mail Wed, 18 Feb 2026 08
- NRx Pharmaceuticals Completes Repayment of $5.4 Million Debt, Positioning Company for Growth in 2026 - Quiver Quantitative hu, 18 Dec 2025 08
- NRXP Analyst Maintains Buy Rating with $34 Target | NRXP Stock N - GuruFocus Wed, 03 Dec 2025 08
- Why Did NRXP Stock Surge 21% Pre-Market Today? - Stocktwits Wed, 14 Jan 2026 08
- HC Wainwright & Co. Reiterates NRx Pharmaceuticals (NRXP) Buy Recommendation - Nasdaq Wed, 01 Oct 2025 07
- NRx Pharmaceuticals (NRXP) Reports Q3 Results and Advances NRX-100 and NRX-101 Regulatory Programs - Yahoo Finance Mon, 17 Nov 2025 08
- Biotech wipes out final $5.4M debt as it pursues depression treatments - Stock Titan hu, 18 Dec 2025 08
- NRx Advances NRX-100 Toward Full FDA Approval Path - The Globe and Mail Wed, 18 Feb 2026 08
- NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion - GlobeNewswire hu, 18 Dec 2025 08
- New Analyst Forecast: $NRXP Given $34.0 Price Target - Quiver Quantitative Mon, 17 Nov 2025 08
- FDA outlines path for NRx to use 65,000 ketamine cases in depression drug bid - Stock Titan ue, 17 Feb 2026 12
- NRx Pharmaceuticals ANDA for KETAFREE received by FDA | NRXP Stock News - Stock Titan ue, 02 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 40000 | 65600 | — | Purchase at price 1.64 per share. | JAVITT JONATHAN C | Chairman of the Board | — | 2024-12-17 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -23.23M | -29.80M | -44.59M | -94.43M |
| TotalUnusualItems | -1.66M | -230.00K | 4.84M | 1.39M |
| TotalUnusualItemsExcludingGoodwill | -1.66M | -230.00K | 4.84M | 1.39M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -25.13M | -30.15M | -39.75M | -93.06M |
| ReconciledDepreciation | 5.00K | 5.00K | 4.00K | 2.00K |
| EBITDA | -24.89M | -30.02M | -39.75M | -93.04M |
| EBIT | -24.90M | -30.03M | -39.75M | -93.05M |
| NetInterestIncome | -186.00K | 374.00K | 249.00K | -18.00K |
| InterestExpense | 230.00K | 120.00K | 0.00 | 18.00K |
| InterestIncome | 44.00K | 494.00K | 249.00K | 0.00 |
| NormalizedIncome | -23.47M | -29.92M | -44.59M | -94.45M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -25.13M | -30.15M | -39.75M | -93.06M |
| TotalExpenses | 18.50M | 27.59M | 44.34M | 94.43M |
| TotalOperatingIncomeAsReported | -18.50M | -27.84M | -44.34M | -115.80M |
| DilutedAverageShares | 10.64M | 7.58M | 6.58M | 4.69M |
| BasicAverageShares | 10.64M | 7.58M | 6.58M | 4.69M |
| DilutedEPS | -2.36 | -3.98 | -6.10 | -74.40 |
| BasicEPS | -2.36 | -3.98 | -6.10 | -74.40 |
| DilutedNIAvailtoComStockholders | -25.13M | -30.16M | -39.75M | -348.88M |
| NetIncomeCommonStockholders | -25.13M | -30.16M | -39.75M | -348.88M |
| OtherunderPreferredStockDividend | 0.00 | 9.00K | 0.00 | 255.82M |
| NetIncome | -25.13M | -30.15M | -39.75M | -93.06M |
| NetIncomeIncludingNoncontrollingInterests | -25.13M | -30.15M | -39.75M | -93.06M |
| NetIncomeContinuousOperations | -25.13M | -30.15M | -39.75M | -93.06M |
| TaxProvision | 0.00 | 0.00 | ||
| PretaxIncome | -25.13M | -30.15M | -39.75M | -93.06M |
| OtherIncomeExpense | -6.44M | -2.94M | 4.33M | 1.39M |
| OtherNonOperatingIncomeExpenses | -4.78M | -2.71M | -505.00K | -21.37M |
| SpecialIncomeCharges | -250.00K | 4.58M | -307.00K | |
| OtherSpecialCharges | 250.00K | 21.25M | ||
| RestructuringAndMergernAcquisition | 0.00 | -4.58M | -20.94M | |
| GainOnSaleOfSecurity | -1.66M | 20.00K | 255.00K | 1.69M |
| NetNonOperatingInterestIncomeExpense | -186.00K | 374.00K | 249.00K | -18.00K |
| InterestExpenseNonOperating | 230.00K | 120.00K | 0.00 | 18.00K |
| InterestIncomeNonOperating | 44.00K | 494.00K | 249.00K | 0.00 |
| OperatingIncome | -18.50M | -27.59M | -44.34M | -94.43M |
| OperatingExpense | 18.50M | 27.59M | 44.34M | 94.43M |
| OtherOperatingExpenses | -1.20M | 250.00K | -771.00K | |
| ResearchAndDevelopment | 6.20M | 13.37M | 17.03M | 20.26M |
| SellingGeneralAndAdministration | 13.51M | 14.22M | 27.31M | 74.94M |
| GeneralAndAdministrativeExpense | 13.51M | 14.22M | 27.31M | 74.94M |
| OtherGandA | 13.51M | 14.22M | 27.31M | 74.94M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 14.59M | 8.39M | 6.64M | 5.88M |
| ShareIssued | 14.59M | 8.39M | 6.64M | 5.88M |
| NetDebt | 5.13M | 4.57M | ||
| TotalDebt | 6.58M | 9.16M | 10.53M | 518.00K |
| TangibleBookValue | -23.22M | -11.74M | 7.41M | 20.81M |
| InvestedCapital | -16.65M | -2.58M | 17.93M | 21.32M |
| WorkingCapital | -18.56M | -12.16M | 10.21M | 20.79M |
| NetTangibleAssets | -23.22M | -11.73M | 7.41M | 20.81M |
| CommonStockEquity | -23.22M | -11.74M | 7.41M | 20.81M |
| PreferredStockEquity | 3.00K | |||
| TotalCapitalization | -18.21M | -11.73M | 10.23M | 20.81M |
| TotalEquityGrossMinorityInterest | -23.22M | -11.73M | 7.41M | 20.81M |
| StockholdersEquity | -23.22M | -11.73M | 7.41M | 20.81M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -3.00K | 0.00 | |
| OtherEquityAdjustments | -3.00K | |||
| RetainedEarnings | -278.27M | -253.15M | -223.00M | -183.24M |
| AdditionalPaidInCapital | 255.03M | 241.41M | 230.34M | 203.99M |
| CapitalStock | 15.00K | 11.00K | 67.00K | 59.00K |
| CommonStock | 15.00K | 8.00K | 67.00K | 59.00K |
| PreferredStock | 0.00 | 3.00K | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 26.87M | 19.05M | 18.41M | 11.92M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 5.01M | 0.00 | 2.82M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 5.01M | 2.82M | ||
| LongTermDebt | 5.01M | 2.82M | ||
| CurrentLiabilities | 21.86M | 19.05M | 15.59M | 11.92M |
| OtherCurrentLiabilities | 5.64M | 17.00K | 37.00K | 4.87M |
| CurrentDebtAndCapitalLeaseObligation | 1.57M | 9.16M | 7.70M | 518.00K |
| CurrentDebt | 1.57M | 9.16M | 7.70M | 518.00K |
| OtherCurrentBorrowings | 1.57M | 9.16M | 7.70M | 518.00K |
| CurrentNotesPayable | 0.00 | 518.00K | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 577.00K | 835.00K | ||
| CurrentProvisions | 4.71M | |||
| PayablesAndAccruedExpenses | 9.37M | 9.04M | 7.84M | 6.53M |
| CurrentAccruedExpenses | 5.24M | 4.40M | 5.77M | 2.84M |
| Payables | 4.13M | 4.63M | 2.08M | 3.69M |
| AccountsPayable | 4.13M | 4.63M | 2.08M | 3.69M |
| TotalAssets | 3.65M | 7.32M | 25.82M | 32.73M |
| TotalNonCurrentAssets | 349.00K | 431.00K | 21.00K | 15.00K |
| OtherNonCurrentAssets | 349.00K | 431.00K | 21.00K | 15.00K |
| CurrentAssets | 3.30M | 6.88M | 25.80M | 32.71M |
| PrepaidAssets | 1.86M | 2.28M | 5.73M | 5.11M |
| Receivables | 0.00 | 6.00K | 7.00K | 0.00 |
| OtherReceivables | 6.00K | 7.00K | ||
| AccountsReceivable | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 1.44M | 4.59M | 20.05M | 27.61M |
| CashAndCashEquivalents | 1.44M | 4.59M | 20.05M | 27.61M |
| CashFinancial | 20.05M | 27.61M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -10.64M | -21.66M | -39.77M | -37.71M |
| RepaymentOfDebt | -8.57M | -4.04M | -518.00K | -1.28M |
| IssuanceOfDebt | 7.08M | 943.00K | 10.02M | 0.00 |
| IssuanceOfCapitalStock | 5.91M | 9.29M | 22.70M | 36.98M |
| CapitalExpenditure | -3.00K | -10.00K | -7.00K | |
| InterestPaidSupplementalData | 374.00K | 885.00K | 0.00 | |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | |
| EndCashPosition | 1.44M | 4.59M | 20.05M | 27.61M |
| BeginningCashPosition | 4.59M | 20.05M | 27.61M | 1.86M |
| ChangesInCash | -3.15M | -15.46M | -7.55M | 25.75M |
| FinancingCashFlow | 7.49M | 6.20M | 32.21M | 63.46M |
| CashFlowFromContinuingFinancingActivities | 7.49M | 6.20M | 32.21M | 63.46M |
| NetOtherFinancingCharges | -896.00K | 11.05M | ||
| ProceedsFromStockOptionExercised | 3.97M | 0.00 | 10.00K | 16.70M |
| NetPreferredStockIssuance | 0.00 | 1.17M | 0.00 | 0.00 |
| PreferredStockIssuance | 0.00 | 1.17M | 0.00 | 0.00 |
| NetCommonStockIssuance | 5.91M | 8.12M | 22.70M | 36.98M |
| CommonStockIssuance | 5.91M | 8.12M | 22.70M | 36.98M |
| NetIssuancePaymentsOfDebt | -1.50M | -3.09M | 9.50M | -1.28M |
| NetShortTermDebtIssuance | -518.00K | -1.28M | ||
| ShortTermDebtPayments | -518.00K | -1.28M | ||
| NetLongTermDebtIssuance | -1.50M | -3.09M | 9.50M | 0.00 |
| LongTermDebtPayments | -8.57M | -4.04M | -518.00K | -1.28M |
| LongTermDebtIssuance | 7.08M | 943.00K | 10.02M | 0.00 |
| InvestingCashFlow | 0.00 | -3.00K | -10.00K | -7.00K |
| CashFlowFromContinuingInvestingActivities | 0.00 | -3.00K | -10.00K | -7.00K |
| NetPPEPurchaseAndSale | 0.00 | -3.00K | -10.00K | -7.00K |
| PurchaseOfPPE | 0.00 | -3.00K | -10.00K | -7.00K |
| OperatingCashFlow | -10.64M | -21.66M | -39.76M | -37.70M |
| CashFlowFromContinuingOperatingActivities | -10.64M | -21.66M | -39.76M | -37.70M |
| ChangeInWorkingCapital | 5.29M | 5.16M | 699.00K | -4.90M |
| ChangeInPayablesAndAccruedExpense | 4.79M | 2.12M | 1.33M | -920.00K |
| ChangeInAccruedExpense | 10.01M | -531.00K | 2.94M | -901.00K |
| ChangeInPayable | -5.22M | 2.65M | -1.61M | -19.00K |
| ChangeInAccountPayable | -5.22M | 2.65M | -1.61M | -19.00K |
| ChangeInPrepaidAssets | 503.00K | 3.04M | -632.00K | -4.81M |
| ChangeInReceivables | 0.00 | 831.00K | ||
| ChangesInAccountReceivables | 0.00 | 831.00K | ||
| OtherNonCashItems | 5.77M | 2.96M | -4.08M | 54.28M |
| StockBasedCompensation | 486.00K | 387.00K | 3.63M | 7.79M |
| DepreciationAmortizationDepletion | 5.00K | 5.00K | 4.00K | 2.00K |
| DepreciationAndAmortization | 5.00K | 5.00K | 4.00K | 2.00K |
| Depreciation | 5.00K | 5.00K | 4.00K | 2.00K |
| OperatingGainsLosses | 2.94M | -20.00K | -255.00K | -1.81M |
| GainLossOnInvestmentSecurities | 1.66M | -20.00K | -255.00K | -1.69M |
| NetIncomeFromContinuingOperations | -25.13M | -30.15M | -39.75M | -93.06M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NRXP
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|